a study of participants with advanced prostate cancer in canada

Conditions: Prostatic Neoplasms

Summary: the purpose of this study is to document the course of advanced prostate cancer in canada in terms of disease progression, real-world treatment, and patient management.


Eligibility criteria:
inclusion criteria: * participant must have a confirmed diagnosis of adenocarcinoma of the prostate * participant must have prostate cancer, as follows: a) nonmetastatic castrate-resistant prostate cancer (nmcrpc): nmcrpc diagnosis at any time; documented castration resistance per prostate cancer working group 3 criteria23 (elevated prostate specific antigen \[psa\] despite testosterone less than (\<) 50 nanograms per deciliter \[ng/dl\] \[\<1.7 nano moles per liter {nmol/l}\]); negative for metastases on conventional imaging (computerized tomography, magnetic resonance imaging, bone scans); prostate specific antigen doubling time (psadt) less than equal to (\<=) 12 months within the last 6 months or beginning treatment with approved next-generation arat for treatment of nmcrpc; b) metastatic castrate-sensitive prostate cancer (mcspc): new mcspc diagnosis in the past 6 months (can be de novo or primary progressive recurrent following local radical therapy); documented metastatic prostate cancer; no more than 12 months of androgen deprivation therapy (adt) in any setting; no more than 6 months of systemic treatment for mcspc (example, approved next generation androgen receptor targeted therapy or chemotherapy\]); c) metastatic castrate-resistant prostate cancer (mcrpc): mcrpc diagnosis at any time; documented metastatic prostate cancer; documented castration resistance per prostate cancer working group 2 criteria (elevated prostate specific antigen \[psa\] despite testosterone less than \[\<\]50 nanogram per deciliter \[ng/dl\] \[\<1.7 nmol/l\]); the first treatment for mcrpc was started in the past 6 months or is scheduled to begin; d) mcrpc (treatment-experienced in the nmcrpc or mcspc setting): mcrpc diagnosis at any time; documented metastatic prostate cancer; documented castration resistance per prostate cancer working group 2 criteria (elevated psa despite testosterone \<50 ng/dl \[\<1.7 nmol/l\]); the first treatment for mcrpc clinical state was started in the past 6 months or is scheduled to begin; disease progression occurred while receiving active treatment (androgen receptor-axis therapy \[arat\] or chemotherapy) in the prior nmcrpc or mcspc clinical state * participant must have a life expectancy of more than 6 months * participant must sign (and/or their legally acceptable representative, if applicable) a participation agreement/informed consent form (icf) allowing data collection and source data verification in accordance with local requirements and/or sponsor policy exclusion criteria: * at the time of screening, patient is currently enrolled in other janssen sponsored clinical study (any indication) or an interventional clinical trial investigating a non health canada approved drug and/or procedure for the treatment and/or monitoring of prostate cancer (janssen or non-janssen company sponsored) * participant is currently enrolled in any observational study sponsored or managed by a janssen company